Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease

Iberdomide in combination with dexamethasone for multiple myeloma

First results of the GMMG-CONCEPT trial for multiple myeloma

PLEIADES: Daratumumab combinations for multiple myeloma

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma

Treatment options for high risk relapsed/refractory multiple myeloma